ARTICLE | Clinical News

Zevalin ibritumomab tiuxetan: Phase II data

June 6, 2011 7:00 AM UTC

A Phase II trial in 60 patients with relapsed/refractory or newly diagnosed high-risk CD20+ NHL who were ineligible for standard ASCT showed that conditioning with 0.8-1.2 mCi/kg Zevalin administered following high-dose chemotherapy with rituximab led to 5-year OS and PFS rates of 72% and 60%, respectively. There were 52 complete responses and 3 good partial responses. Data are being presented at the American Society of Clinical Oncology meeting in Chicago. ...